FDA Reinstates Vinay Prasad After Brief Departure

Pro-establishment narrative

Prasad's return to the CBER, at the request of the FDA, was necessary to restore scientific vigor. His track record shows a commitment to evidence-based medicine, having demanded stronger data for COVID vaccines and setting stricter protocols for experimental treatments. The agency needs leaders like Prasad who prioritize patient safety over industry pressure.